The revised outlook compares with the Capital IQ estimate for $253.6 million.
The forecast includes $16.7 million of Section 351 products sold in the US for the six months ended June 30. Section 351 of the Public Health Service Act refers to a set of products that will be regulated as biologicals. Biological products include "blood-derived products, vaccines, in-vivo diagnostic allergenic products, immunoglobulin products, products containing
cells or microorganisms, and most protein products," according to a US Food and Drug Administration document.
Adjusted net sales for the fiscal year 2020 stood at $240.5 million, which included $31.8 million of Section 351 product, the company said.